AJMC® in the Press, August 25, 2023

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.

January 27th 2026

Tildrakizumab Shows Long-Term Psoriasis Control for Hard-to-Treat Areas

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Tildrakizumab at 100-mg and 200-mg doses showed long-term effectiveness for managing psoriasis in challenging areas in a real-world study.

January 20th 2026

Health Equity & Access Weekly Roundup: January 30, 2026

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Virtual Reality Intervention Increased Empathy for Patients With MG

Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.

Virtual reality | Image credit: nuclear_lily - stock.adobe.com

Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL

Empathy, knowledge, and attitudes in care for patients with myasthenia gravis were improved when using a patient-centric immersive virtual reality intervention.

Related Content

January 31st 2026

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.

January 27th 2026

Tildrakizumab Shows Long-Term Psoriasis Control for Hard-to-Treat Areas

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Tildrakizumab at 100-mg and 200-mg doses showed long-term effectiveness for managing psoriasis in challenging areas in a real-world study.

January 20th 2026

Health Equity & Access Weekly Roundup: January 30, 2026

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Virtual Reality Intervention Increased Empathy for Patients With MG

Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.